Physician profile
Jay K Johnson
NPI 1043224264
$4,757.44
in general payments reported to CMS, 2019-2025
36 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $32.98 · 2021: $300 · 2022: $513 · 2023: $872 · 2024: $1,296 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,561 · Education: $91.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,560.74 |
| Education | $91.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $812.85 | 2021-2025 | Vyepti |
| Genentech USA, INC. | $495.48 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Ucb, INC. | $339.99 | 2019-2025 | Rystiggo, Zilbrysq, Fintepla |
| Tg Therapeutics, INC. | $284.31 | 2024-2025 | |
| Csl Behring | $259.46 | 2021-2025 | Hizentra |
| Abbvie INC. | $250.17 | 2022-2025 | |
| Argenx US, INC. | $198.51 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $193.04 | 2019-2024 | Tysabri, Vumerity |
| Eisai INC. | $165.67 | 2022-2024 | |
| Celgene Corporation | $161.54 | 2021-2025 | Zeposia |
| Lilly USA, LLC | $142.74 | 2022-2025 | Kisunla, Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $133.35 | 2022-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $129.62 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $121.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $116.57 | 2022-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $113.11 | 2020-2025 | Nuplazid |
| Octapharma USA, INC. | $112.20 | 2023 | Panzyga |
| Vanda Pharmaceuticals INC. | $102.59 | 2025 | Ponvory |
| Abbott Laboratories | $89.24 | 2025 | Freestyle Libre 3 |
| Emd Serono, INC. | $85.92 | 2025 | |
| Pfizer INC. | $68.35 | 2023-2024 | |
| Corcept Therapeutics | $61.64 | 2024-2025 | Korlym |
| Novo Nordisk INC | $39.66 | 2024-2025 | Ozempic, Rybelsus |
| Banner Life Sciences, LLC | $37.59 | 2023 | |
| Amgen INC. | $31.75 | 2021-2022 | |
| Tanabe Pharma America, INC. | $28.47 | 2023 | |
| Electromed, INC. | $21.88 | 2024 | Smartvest |
| Cequr Corporation | $20.47 | 2024-2025 | Cequr Simplicity |
| Avion Pharmaceuticals | $20.42 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.26 | 2022 | |
| Genzyme Corporation | $19.99 | 2021 | |
| Mylan Specialty L.P. | $18.84 | 2022 | |
| Medtronic, INC. | $16.30 | 2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $15.80 | 2024 | Gvoke Hypopen |
| Baxter Healthcare | $14.27 | 2023 | Hillrom - Life 2000 Ventilation System |
| Astrazeneca Pharmaceuticals LP | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.